Lexicon Pharmaceuticals Inc Market Cap ($657.41 Million)
Market Cap & Net Worth: Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc market cap. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a market capitalization of $657.41 Million ($657.41 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10591 globally and #2829 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lexicon Pharmaceuticals Inc's stock price $1.48 by its total outstanding shares 444196390 (444.20 Million). Also see Lexicon Pharmaceuticals Inc (LXRX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Lexicon Pharmaceuticals Inc Market Cap History (2015–2026)
Lexicon Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $5.91 Billion to $657.41 Million (-16.79% CAGR). Check LXRX stock price and chart for real-time trading data and today's change.
Index Memberships
Lexicon Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #295 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1100 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.04% | #176 of 263 |
Weight: Lexicon Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lexicon Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lexicon Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LXRX shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
10.26x
Lexicon Pharmaceuticals Inc's market cap is 10.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.14 Billion | $83.34 Million | -$141.43 Million | 73.72x | N/A |
| 2017 | $4.39 Billion | $90.33 Million | -$129.05 Million | 48.58x | N/A |
| 2018 | $2.95 Billion | $63.21 Million | -$120.55 Million | 46.66x | N/A |
| 2019 | $1.84 Billion | $322.07 Million | $130.13 Million | 5.72x | 14.17x |
| 2020 | $1.52 Billion | $24.00 Million | -$58.57 Million | 63.31x | N/A |
| 2021 | $1.75 Billion | $298.00K | -$87.76 Million | 5872.93x | N/A |
| 2022 | $848.42 Million | $139.00K | -$101.94 Million | 6103.71x | N/A |
| 2023 | $679.62 Million | $1.20 Million | -$177.12 Million | 564.47x | N/A |
| 2024 | $328.04 Million | $31.08 Million | -$200.40 Million | 10.55x | N/A |
| 2025 | $510.83 Million | $49.80 Million | -$50.34 Million | 10.26x | N/A |
Competitor Companies of LXRX by Market Capitalization
Companies near Lexicon Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see Lexicon Pharmaceuticals Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Lexicon Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Lexicon Pharmaceuticals Inc (2015–2026)
Market capitalization of Lexicon Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Lexicon Pharmaceuticals Inc's market cap moved from $5.91 Billion to $ 657.41 Million, with a yearly change of -16.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $657.41 Million | +28.70% |
| 2025 | $510.83 Million | +55.72% |
| 2024 | $328.04 Million | -51.73% |
| 2023 | $679.62 Million | -19.90% |
| 2022 | $848.42 Million | -51.52% |
| 2021 | $1.75 Billion | +15.20% |
| 2020 | $1.52 Billion | -17.59% |
| 2019 | $1.84 Billion | -37.50% |
| 2018 | $2.95 Billion | -32.79% |
| 2017 | $4.39 Billion | -28.56% |
| 2016 | $6.14 Billion | +3.91% |
| 2015 | $5.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Lexicon Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $657.41 Million USD |
| MoneyControl | $657.41 Million USD |
| MarketWatch | $657.41 Million USD |
| marketcap.company | $657.41 Million USD |
| Reuters | $657.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more